drugset / Trial / NCT03950297
Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A
NaSingle-groupOpen-labelTreatment
Summary
Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A in the Patients with Locally advanced/Metastatic Solid Tumors
Timeline
- Start
- 2019-05-01
- Primary completion
- 2020-10-24
- Completion
- 2022-05-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 609A | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | 609A | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | 609A | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | 609A | Monoclonal antibody | 200 mg | Intravenous |